Peperomin E reactivates silenced tumor suppressor genes in lung cancer cells by inhibition of DNA methyltransferase

Xin-zhi Wang, Ying Cheng, Kui-long Wang, Rui Liu, Xiao-lin Yang, Hong-mei Wen, Chuan Chai, Jing-yu Liang and Hao Wu

Advanced lung cancer has poor prognosis owing to its low sensitivity to current chemotherapy agents. Therefore, discovery of new therapeutic agents is urgently needed. In this study, we investigated the antitumor effects of peperomin E, a secolignan isolated from Peperomia dindygalensis, a frequently used Chinese folk medicine for lung cancer treatment. The results indicate that peperomin E has antiproliferative effects, promoting apoptosis and cell cycle arrest in non-small-cell lung cancer (NSCLC) cell lines in a dose-dependent manner, while showing lower toxicity against normal human lung epithelial cells. Peperomin E inhibited tumor growth in A549 xenograft BALB/c nude mice without significant secondary adverse effects, indicating that it may be safely used to treat NSCLC. Furthermore, the mechanisms underlying the antitumor effects of peperomin E have been investigated. Using an in silico target fishing method, we observed that peperomin E directly interacts with the active domain of DNA methyltransferase 1 (DNMT1), potentially affecting its genome methylation activity. Subsequent experiments verified that peperomin E decreased DNMT1 activity and expression, thereby decreasing global methylation and reactivating the epigenetically silenced tumor suppressor genes including RASSF1A, APC, RUNX3, and p16INK4, which in turn activates their mediated pro-apoptotic and cell cycle regulatory signaling pathways in lung cancer cells. The observations herein report for the first time that peperomin E is a potential chemotherapeutic agent for NSCLC. The anticancer effects of peperomin E may be partly attributable to its ability to demethylate and reactivate methylation-silenced tumor suppressor genes through direct inhibition of the activity and expression of DNMT1.

Lung cancer is the leading cause of cancer-related death worldwide (1). Owing to a large smoking population and serious air pollution, the incidence of lung cancer has grown rapidly in China, resulting in a large social and economic burden (2-4). Diagnosis of lung cancer, especially non-small-cell lung cancer (NSCLC), often occurs so late that approximately two-thirds of patients have lost the opportunity for radical surgery (4). Four chemotherapeutic regimens – cisplatin and gemcitabine, cisplatin and docetaxel, carboplatin and paclitaxel, and cisplatin and paclitaxel – have been used for clinical treatment of NSCLC (5). However, the aforementioned chemotherapy is not very efficient and causes severe side-effects, including neurotoxicity, renal damage, and bone marrow inhibition (6-8). Patients usually die within 1-2 years of diagnosis. Therefore, identifying new drug targets and novel therapeutic agents to reduce mortality and improve quality of life for patients with advanced lung cancer remains a major goal for researchers and drug developers.

Peperomia dindygalensis (Piperaceae) is commonly used in southern China as a folk medicine to treat various cancers (9). Chemical analysis of this plant has indicated that it contains secolignans (10-13), tetrahydrofuran lignans (14), flavonoids (15), and polyketides (16-18). Secolignans are characteristic of the Peperomia species and have been shown to possess various bioactivities that make them effective treatments against tumors (10-13,19), inflammation (20), and HIV infection (21). Among the secolignans that have been isolated, peperomin E (PepE; Fig. 1a), which is characterized by an α-methylene-γ-butyrolactone moiety, has shown the strongest inhibition of cancer cell growth in lung (11), breast (19), leukemia (19), liver (11), and cervical cancer cells (19). However, antitumor activity and safety of PepE have not been investigated in vivo, and the mechanism of its anticancer activity has not been elucidated.

In this study, we evaluated the safety and efficacy of PepE for treatment of NSCLC. We undertook an in silico target fishing study of PepE, which showed that PepE possessed the highest affinity to the active pocket of the DNA methyltransferase 1 (DNMT1) enzyme. Subsequent experiments investigated PepE activity against DNMT1 activity and expression and evaluated the effect of PepE on the expression of the epigenetically silenced tumor suppressors (i.e., RASSF1A and
APC genes in A549 cells, p16INK4 gene in H1299 cells, and RUNX3 gene in NCI-H460 cells), which may further activate pro-apoptotic and cell cycle regulatory signaling pathways in these NSCLC cell lines.

Materials and Methods

Plant material. *Peperomia dindygulensis* (whole plant) was collected from Yunnan Province, China, in February 2014 and identified by Professor She-ban Pu from the China Pharmaceutical University (Nanjing, China). Voucher specimens (PDg 2014-2) were deposited at the College of Pharmacy, Nanjing University of Chinese Medicine, (Nanjing, China).

Chemicals and antibodies. Peperomin E was previously isolated from *P. dindygulensis* in our laboratory by a series of chromatographic procedures. Its structure (Fig. 1) was unequivocally elucidated by spectroscopic methods (i.e., mass spectrometry, proton (1H) nuclear magnetic resonance (NMR), and carbon-13 (13C) NMR; Fig. S1). Purity of PepE was verified by HPLC peak area normalization and peak purity analysis. Results showed that the purity was >98% and the peak purity angle/peak purity threshold was <1 (Fig. S2).

Peperomin E powder was dissolved in DMSO (Sigma-Aldrich, St. Louis, MO, USA) to produce a 10−2 M solution, which was stored at −20°C. 5-Aza-2-deoxycytidine (5-Aza-dC, CAS No. 2353-33-5) was purchased from Sigma-Aldrich and dissolved in water immediately before use.

Monoclonal rabbit antibodies against DNMT1, Ras association domain family member 1 (RASSF1A), macrophage stimulating (MST1), MST2, Bax, Bcl-2, cleaved caspase 3, cleaved caspase 9, poly(ADP-ribose) polymerase (PARP), and GAPDH were all purchased from Abcam (San Francisco, CA, USA). Cyclin D1, runt related transcription factor 3 (RUNX3), p16INK4, adenomatous polyposis coli (APC), modulator of apoptosis 1 (MOAP1), Connector enhancer of kinase suppressor of ras 1 (CNK1), β-catenin, and HRP-conjugated secondary antibodies (goat anti-rabbit) were all purchased from Santa Cruz Biotechnology (Dallas, TX, USA). Gibco FBS and high-glucose DMEM media were obtained from Thermo Fisher Scientific (Rockford, IL, USA).

Cell culture. BEAS-2B, A549, H1299, and NCI-H460 cells were obtained directly from ATCC (Manassas, VA, USA) and passaged in our laboratory for <6 months after resuscitation. Cells were cultured and maintained in high-glucose DMEM supplemented with 10% (v/v) FBS, 100 U/mL penicillin, and 100 µg/mL streptomycin and grown at 37°C in a 5% CO2 humidified incubator.

**In vitro cytotoxicity assay.** The effects of PepE on lung cancer cell viability were investigated using MTT assays. The tumor cells (4 × 10⁴ cells/well in 100 µL medium) were seeded into 96-well plates for 24 h before drug treatment. We used 5-Aza-dC, which exhibits activity against lung cancer cells, as a positive control. After treatment with various concentrations of PepE (0–100 µM) and 5-Aza-dC for 48 h, the cell plates were treated with MTT solution (20 µL; 5 mg/mL in PBS) for an additional 4 h at 37°C. The formazan crystals in viable cells were solubilized with DMSO (150 µL) and the absorbance was measured on a microplate reader (ELX 800; BioTek Instruments, Winooski, VT, USA) at a wavelength of 490 nm. Cell viability was calculated as the inhibition ratio (I%) using the following equation (optical density at 490 nm [OD490]):

\[
I% = \frac{OD_{490}(\text{control}) - OD_{490}(\text{treated})}{OD_{490}(\text{control})} \times 100%.
\]

**In vivo tumorigenicity assay.** Six-week-old male BALB/c athymic nude mice were purchased from Cavens animal center (Changzhou, China; No. SCXK 2011-0003). The mice were kept under specific pathogen-free conditions, provided with sterilized food and water, and housed in positive pressure isolators with 12:12-h light:dark cycles. A549 cells (5.0 × 10⁶; 0.2 mL) were injected s.c. into the right armpit. Tumor growth and body weight were monitored every other day. When tumor diameter reached 5 mm, mice were randomly divided into treatment and control groups (*n* = 6/group). Peperomin E was dissolved in soybean oil and given by i.v. injection at a dose of 25 or 50 mg/kg every other day. As a positive control, 5-Aza-dC was given by i.v. injection at a dose of 5 mg/kg twice a week. The control group received soybean oil only. Mice were treated for 3 weeks. Tumor volume was calculated using the formula *V* = 1/2 (*A* × *B*²), where *A* indicates the length and *B* indicates the width of the tumor as measured by calipers. At the end of the treatment period, blood samples were collected from the retro-orbital plexus. Serum was tested for alanine aminotransferase and creatinine levels. Plasma was tested for blood platelet and neutrophil granulocyte cell levels. Analyses were carried out using a DXC800 Synchrone spectrophotometer (Beckman Coulter, Brea, CA, USA). Mice were then killed and the tumor tissue, lung, liver, and kidney were surgically removed from the body, fixed in 10% neutral formalin, and embedded in paraffin for analysis. Experiments were carried out in accordance with the Guidelines for Animal Experimentation and approved by the Animal Ethics Committee at Nanjing University of Chinese Medicine.

**Apoptosis and cell cycle analysis.** Cell apoptosis was determined using an annexin V–FITC apoptosis detection kit (Key-Gen Biotechnology, Nanjing, China) according to the manufacturer’s instructions. Briefly, A549 cells were treated with PepE (0.5, 2.0, or 4.0 µM) or 5-Aza-dC (2.0 µM) for 48 h, the cell plates were treated with MTT solution (20 µL; 5 mg/mL in PBS) for an additional 4 h at 37°C. The formazan crystals in viable cells were solubilized with DMSO (150 µL) and the absorbance was measured on a microplate reader (ELX 800; BioTek Instruments, Winooski, VT, USA) at a wavelength of 490 nm. Cell viability was calculated as the inhibition ratio (I%) using the following equation (optical density at 490 nm [OD490]):

\[
I% = \frac{OD_{490}(\text{control}) - OD_{490}(\text{treated})}{OD_{490}(\text{control})} \times 100%.
\]
Inhibitor sample OD - Blank OD

NCI-H460, and H1299 cells were treated with PepE (0.5, free RNase A at 37°C for 30 min before flow cytometry analysis (FACSCalibur; Becton Dickinson). The distribution of cells in distinct cell cycle phases was analyzed using CellQuest software (Becton Dickinson).

Cell cycle analysis was undertaken using a cell cycle detection kit (KeyGen Biotechnology) according to the manufacturer’s instructions. Briefly, A549 cells were treated with PepE (2.0 μM) or 5-Aza-dC (2.0 μM) for 48 h. The cells were harvested and fixed with 70% alcohol at 4°C for 12 h. DNA was stained with propidium iodide in the presence of 1% DNase-free RNase A at 37°C for 30 min. The stained samples were quantified by using a calibration curve between the peak area ratio of 5mdC to dG (A5mdC/A5dG) versus [5mdC]/[dG]%. In vitro DNA methyltransferase inhibition assay. Nuclear extracts were prepared from A549 cells using the EpiQuik nuclear extraction kit (Cat. No. OP-0002-1; Epigentek) following the manufacturer’s instructions and stored at -80°C. Nuclear extract quantity was determined using Quick Start Bradford protein assay kit (Bio-Rad, Hercules, CA, USA). The DNMT activity was determined using an EpiQuik DNMT activity/inhibition assay kit (Cat. No. P-3001; Epigentek) following the manufacturer’s instructions. Briefly, 10 μg A549 nuclear extract was added to sample wells coated with cytosine-rich DNA substrate. Then PepE or 5-Aza-dC was added to the inhibition wells; control wells received DMSO only. The reactions were carried out spectrophotometrically at 450 nm using the 96-well Multiskan GO microplate reader (Thermo Scientific). Inhibition of DNMT was calculated using the following formula: IC50 was determined from the dose-inhibition curves.

DNMT inhibition% = \left(1 - \frac{\text{Inhibitor sample OD - Blank OD}}{\text{No inhibitor sample OD - Blank OD}}\right) \times 100\%.

Bisulfite modification and methylation-specific PCR. DNA was extracted from PepE-treated and untreated A549, NCI-H460, and H1299 cells using the DNeasy tissue kit (Qiagen) according to the manufacturer’s instructions. Extracted DNA was modified with sodium bisulfite and analyzed according to a modification of the method described by Herman et al. Briefly, 1 μg genomic DNA was modified with bisulfite using a CpGenome DNA modification kit (Chemicon, Temecula, CA, USA). The modified DNA was amplified with primers for the methylated and unmethylated gene sequences designed according previously published reports (Table S1). The reactions were carried out using the Veriti 96-well thermal cycler (Applied Biosystems). Polymerase chain reaction conditions are listed in Table S2. The PCR products were then loaded onto 3.5% low-range agarose gels (Thermo Fisher Scientific), stained with ethidium bromide, and observed under UV illumination using Gel Doc XR (Bio-Rad), CpGenome Universal methylated DNA and unmethylated DNA (Chemicon) were used as positive controls for DNA methylation and unmethylation.

Quantitative real-time PCR assays. RNA was extracted from NSCLC cells (including A549, NCI-H460, and H1299 cells) using the RNeasy RNA isolation kit (Qiagen), and on-column DNA digestion was done using the RNase-Free DNase Set (Qiagen). cDNA was synthesized from 2 μg RNA with the iScript cDNA synthesis kit (Bio-Rad) according to the manufacturer’s instructions, and gene expression levels of DNMT1, RASSF1A, and APC in A549 cells, RUNX3 in NCI-H460 cells, and p16/INK4a in H1299 cells were quantitatively measured in triplicate with a real-time quantitative PCR system (Tianlong TL988; IV; Tianlong Scientific Technology Corp., Xi’an, China), using SYBR Green I (Applied Biosystems) and corresponding primers (Table S3, designed by the software Primer premier 5.0 and

synthesized by Genewiz Corp., Suzhou, China). The PCR conditions are listed in Table S4. The mRNA levels of all tested genes were normalized against GAPDH, results were reported as fold-change (2^(-ΔΔCt)) relative to non-treated samples. To visually evaluate the mRNA expression of RASSF1A, APC, RUNX3, and p16INK4a genes, the amplified products derived from the Veriti 96-well thermal cycler (Applied Biosystems) were loaded onto 1.8% agarose gels containing ethidium and observed using the Gel Doc XR system (Bio-Rad).

**Western blot analysis** Protein levels were analyzed by Western blotting. Briefly, A549, NCI-H460, or H1299 cells were cultured at 2 × 10^5 cells/mL in a 100 in 20-mm cell culture dish and treated with different doses of PepE or 5-Aza-dC (2.0 μM) for 48 h. Subsequently, the cells were collected and incubated in RIPA buffer (Santa Cruz Biotechnology). Cell lysates were centrifuged and used as protein extracts. The concentration of each extract was determined by Bradford protein assay (Bio-Rad). Proteins (approximately 25–50 μg) were subjected to 10% SDS-PAGE, transfer, and incubation. Proteins were then transferred onto a nitrocellulose transfer membrane (Abcam) and blocked for 1 h using 5% non-fat dried milk at room temperature. After incubating in TBS/0.1% Tween-20, primary antibodies against DNMT1, RASSF1A, MST1/2, Bax, Bcl-2, cleaved caspase 3, cleaved PARP, and cleaved caspase 3 (polyclonal, Santa Cruz Biotechnology) were added (1:1000 v/v). The primary antibody bands were visualized by 3,3′-diaminobenzidine staining (Dako, Carpinteria, CA, USA). Sections were observed under an inverted phase contrast microscope (IX51; Olympus, Tokyo, Japan). Photographs were taken and analyzed using Image-Pro Plus software (Media Cybernetics, Inc, Rockville, MD, USA).

**Statistical analysis** Statistical analyses were undertaken using GraphPad Prism 6.0 software (Graphpad software Inc., La Jolla, CA, USA). One-way ANOVA followed by Student’s t-test was used for multiple comparisons. P < 0.05 was considered significant and P < 0.01 was considered more significant.

**Results** **Peperomin E inhibits cell viability, promotes apoptosis, and induces G0/S phase cell cycle arrest of lung cancer cells in vitro and in vivo.** Human lung cancer cell lines A549, NCI-H460, and H1299 were treated with PepE at various concentrations (0–100 μM) for 48 h. The inhibitory effect of PepE on these cell lines was dose-dependent (Fig. 1b). The IC_{50} values were as follows: A549, 2.177 μM; H1299, 6.862 μM; and NCI-H460, 6.485 μM. Selectivity for tumor versus normal cells was determined by comparing the efficacy of PepE on the above tumor cells to its efficacy on the normal human lung epithelial cell line BEAS-2B. Inhibition of PepE on BEAS-2B cells was far less potent than on the gastric tumor cell lines (Fig. 1b), indicating that PepE is specific for cancer cells.

Peperomin E given at 25 or 50 mg/kg every other day slowed the growth of A549 tumors in BALB/c mice (Fig. 2a). Mice treated with PepE showed significantly lower tumor volume on day 21 compared to negative control mice (P < 0.01, Fig. 2a). As indicated in Figure 2(a), the proliferation inhibition efficacy of PepE at 50 mg/kg every day was lower than that of 5-Aza-dC (positive control) at 10 mg/kg twice a week (57.3% and 67.1% inhibition, respectively). However, lower toxicity was observed in PepE than in 5-Aza-dC-treated mice based on parallel monitoring of body weight. As shown in Figure 2(b), 5-Aza-dC treatment led to significant weight loss in mice with xenograft tumors compared with PepE treatment. As shown in Figure 2(c), no significant alterations of blood biochemical parameters were observed after PepE treatment. Furthermore, no significant histopathological alterations were found in the lung, liver, or kidney after PepE treatment (Fig. S4). However, 5-Aza-dC treatment led to a significant decrease in platelet and neutrophil granulocyte cell counts in xenograft mice compared with negative control mice (Fig. 2c). These results indicated that PepE can effectively protect against tumor growth in vivo with fewer adverse effects than 5-Aza-dC.

Typical characteristics of apoptosis, such as cell shrinkage and pyknosis, were observed in PepE-treated lung cancer cells, indicating that PepE may cause lung cancer cell death by inducing cell apoptosis. Therefore, flow cytometry using FITC–annexin V/propidium iodide staining coupling were used to detect cancer cell apoptosis and Western blot analysis was used to detect apoptosis-related proteins after PepE treatment. Following 48 h of treatment, the proportion of apoptotic cells was significantly higher in cells exposed to 0.5 μM PepE compared with vehicle (P < 0.01; Fig. 3a). A dose-dependent increase was also observed in the percentage of apoptotic cells (17.5%, 24.9%, and 39.2% following treatment with 0.5, 2.0, and 4.0 μM PepE, respectively) (Fig. 3a). Meanwhile, a concentration-dependent increase of the pro-death protein Bax was observed following PepE treatment, whereas Bcl-2 levels decreased with increasing PepE concentration (Fig. 3b). Decrease in the Bcl-2/Bax ratio led to the cleavage of caspase 9 and caspase 3 (Fig. 3b), and cleaved PARP, a hallmark of apoptosis, significantly increased after PepE treatment (Fig. 3b). The above results indicated that PepE may cause lung cancer cell death by inducing cell apoptosis. The extent of apoptosis in tumor tissues was further examined using the TUNEL assay. The PepE (50 mg/kg) and 5-Aza-dC groups showed more TUNEL-positive cells than the control group (Fig. 3c), indicating that PepE can also induce lung cancer cell apoptosis in vivo.

The cell cycle progression of A549 cells was also evaluated. As shown in Figure 4(a), the percentage of cells in G1 was significantly increased after treatment with 2 μM PepE and 5-Aza-dC for 48 h than with the negative control (PepE, 77.3% vs 57.4%; 5-Aza-dC, 84.7% vs 57.4%; P < 0.01), suggesting that 2 μM PepE arrested A549 cells in the G1 phase. The
proportion of sub-G1 phase cells was significantly increased in A549 cells exposed to 2 μM PepE and 5-Aza-dC compared with negative control (PepE, 23.4% vs 2.3%; 5-Aza-dC, 37.1% vs 2.3%; P < 0.01), suggesting that 2 μM PepE led to a notable level of cell apoptosis (Fig. 4a). The expression of cell cycle-related protein cyclin D1 in A549 cells was then evaluated following PepE treatment. A concentration-dependent decrease of cyclin D1, which can lead to G1/S-phase cell cycle arrest in cancer cells, was observed in vitro after PepE treatment (Fig. 4b).

The above results indicate that the antiproliferation effect of PepE was mediated primarily by promoting apoptosis and suppressing the cell cycle in vitro and in vivo.

Identification of potential PepE targets by computational target fishing. The top 10 tumor-related targets, ranked by LibDock score in descending order, are shown in Table 1. Human DNMT1 (PDB ID: 3SWR) and mouse DNMT1 (PDB ID: 3AV6) ranked first and second, respectively. Pepperomin E docking on DNMT1 (PDB ID: 3SWR) active sites (Fig. 5a) showed three hydrogen bond formations with glycine (GLY1147), glutamic acid (GLU1168), and phenylalanine (PHE1145). Similarly, molecular binding of 5-Aza-dC, a standard inhibitor of DNMT1, showed five hydrogen bonds with glycine (GLY1147), glutamic acid (GLU1168, GLU1266), asparagine (ASN1578), and phenylalanine (PHE1145). Moreover, as shown in Figure 5(b) and Table 2, superimposition of co-crystallized sinefungin and docked compounds PepE and 5-Aza-dC on DNMT1 showed similar binding affinity. Pepperomin E bound well within the DNMT1 active pocket (Fig. 5b), but showed slightly lower binding affinity than 5-Aza-dC and sinefungin. The molecular docking 2-D diagram for PepE, sinefungin, 5-Aza-dC, and S-adenosylmethionine (Fig. 5c–f) shows interaction of DNMT1 hydrophobic amino acid residues with bond ligands.

DNA methyltransferase 1 is responsible for duplicating the pattern of DNA methylation during replication and is essential for mammalian development. Targeting DNMT1 can strongly inhibit the formation of tumors by reverting the hypermethylation of tumor suppressor genes and suppressing cancer-specific cellular phenotypes. Typical DNMT1 inhibitor such as 5-Aza-dC can inhibit DNMT1 activity by covalent binding to the active site of the enzyme then blocking the entry of key nucleotide cytosine into such site, thus, preventing DNA methylation of cancer cells. The in silico modeling results suggested that PepE might have the same inhibitory effect on DNMT1 by showing similar binding affinity to the active site of this enzyme.
Fig. 3. Effects of peperomin E (PepE) on the changes of apoptotic rate and apoptosis-related proteins of A549 non-small-cell lung cancer cells. (a) The Annexin V/PI double-staining assay of A549 cells, cell populations in the lower right (Annexin+/PI−) represents early apoptotic cells, upper right (Annexin+/PI+) represents late apoptotic cells; (b) Expression of Bcl-2, Bax, cleaved caspase 9, cleaved caspase 3 and PARP proteins in A549 cells, the intensity of the bands was quantified by optical density (OD) and normalized to the OD of β-actin; and (c) Representative TUNEL staining of tumors harvested 21 days after subcutaneous inoculation is shown for control group, 50 mg/kg PepE and 5-Aza-dC treatment group. Data are presented as means ± SD (n = 3 for a and b; n=6 for c). **P < 0.01. 5-Aza-dC, 5-Aza-2-deoxycytidine; PI, propidium iodide.
Peperomin E reactivates TSGs in lung cancer

Table 1. Top 10 potential tumor-related targets of peperomin E predicted by LibDock of Discovery Studio 4.0

<table>
<thead>
<tr>
<th>Rank</th>
<th>PDB ID.</th>
<th>Libdock score</th>
<th>Targets</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>3SWR</td>
<td>155.7</td>
<td>DNA (cytosine-5)-methyltransferase 1 (human)</td>
</tr>
<tr>
<td>2</td>
<td>3AV6</td>
<td>139.5</td>
<td>DNA (cytosine-5)-methyltransferase 1 (mouse)</td>
</tr>
<tr>
<td>3</td>
<td>3TLM</td>
<td>136.9</td>
<td>Sarcoplasmic/endoplasmic reticulum calcium ATPase 1 (cattle)</td>
</tr>
<tr>
<td>4</td>
<td>4EKL</td>
<td>134.8</td>
<td>RAC-alpha serine/threonine-protein kinase (human)</td>
</tr>
<tr>
<td>5</td>
<td>1TST</td>
<td>132.1</td>
<td>Sarcoplasmic/endoplasmic reticulum calcium ATPase 1 (rabbit)</td>
</tr>
<tr>
<td>6</td>
<td>4FYJ</td>
<td>130.4</td>
<td>Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform (human)</td>
</tr>
<tr>
<td>7</td>
<td>3KKQ</td>
<td>130.1</td>
<td>RAC-alpha serine/threonine-protein kinase (human)</td>
</tr>
<tr>
<td>8</td>
<td>3NK5</td>
<td>129.1</td>
<td>Bcl-2 like protein 1 (human)</td>
</tr>
<tr>
<td>9</td>
<td>3MLB</td>
<td>124.0</td>
<td>Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform (human)</td>
</tr>
<tr>
<td>10</td>
<td>3OW4</td>
<td>123.8</td>
<td>RAC-alpha serine/threonine-protein kinase (human)</td>
</tr>
</tbody>
</table>

Peperomin E inhibits DNA methyltransferase enzyme activity and expression, thereby decreasing global DNA methylation in NSCLC cells. To validate the results of in silico virtual screening, we determined DNMT activity in the nuclear extract of A549 cells after treatment with various concentrations of PepeE (10^{-3}–10^{0} \text{ nM}) or 5-Aza-dC (positive control). We found that both PepeE and 5-Aza-dC inhibited DNMT activity in the nuclear extracts in a dose-dependent manner (Fig. 6a), with IC_{50} values of 2.05 and 2.15 \text{ nM}, respectively.

To examine whether PepeE induces degradation of DNMT1, we carried out Western blot analysis with extracts from A549 cells treated with PepeE at different concentrations (1.0, 4.0, and 8.0 \text{ nM}) and found that PepeE treatment was associated with a statistically significant dose-dependent depletion of DNMT1 in 4.0 and 8.0 \text{ nM} doses (P < 0.01, Fig. 6b). Next, we measured DNMT1 mRNA levels by quantitative RT-PCR (RT-qPCR) following treatment with PepeE. As shown in Figure 6(c), DNMT1 mRNA levels decreased in a dose-dependent manner, indicating that, unlike 5-Aza-dC, which induces degradation of DNMT1 through the proteosomal pathway, PepeE mediates depletion of DNMT1 by altering its mRNA expression. Previous studies indicated that the Sp1/nuclear factor-κB (NF-κB) pathway positively modulates the gene expression of DNMT1. Therefore, the changing of Sp1 and NF-κB (p65) proteins in A549 cells after PepeE treatment was further investigated. As shown in Figure 6(d), protein levels of Sp1 and NF-κB (p65) were both significantly down-regulated in a dose-dependent manner after PepeE treatment (P < 0.01). This result indicated that the transcriptional repression activity of PepeE against DNMT1 might be owing to its ability to reduce the expression of NF-κB (p65) and Sp1, which correlated with a reduction in binding of these transcription factors to the DNMT1 promoter. This conjecture requires further experimental proof in following studies.

Because DNMT catalyzes the process of DNA methylation, we assessed whether PepeE alters genomic DNA methylation levels in NSCLC cells or xenograft tumor tissues. Typical ultra-fast liquid chromatography tandem mass spectrometry multiple reaction monitoring ion chromatograms for dG and 5-mdC are shown in Figure S5(A,B). Calibration curves of 5-mdC and dG (0–10%) are shown in Figure S5(C) (R^2 = 0.9995). DNA methylation levels in NSCLC cells treated with 2.0 and 4.0 \text{ nM} PepeE (i.e., 2.86% and 2.61% methylation in A549 cells, 3.61% and 3.30% methylation in NCI-H460 cells, and 3.47% and 3.08% methylation in H1299 cells, respectively) were significantly lower than those treated with the negative control (i.e., 3.84%, 4.77%, and 4.20% methylation in untreated A549, NCI-H460, and H1299 cells, respectively) (Fig. 7a). Similarly, Figure 7(b) shows that genomic methylation levels were significantly reduced in xenograft tumor tissues collected from mice treated...
Fig. 5. Molecular interactions between peperomin E and DNA methyltransferase 1. (a) Structure model of DNMT1 (PDB: 3SWR) with co-crystallized ligand Sinefugin binding site (yellow color). (b) Superimposition of the best conformation of 5-Aza-dC (in red), Sinefugin (in green), S-adenosylmethionine (SAM, in blue) and PepE (in yellow) docked in the active site pocket of DNMT1 by Discovery Studio 4.0 Libdock protocol. 2-D diagrams illustrating protein-ligand interactions of (c) SAM, (d) Sinefugin, (e) 5-Aza-dC and (f) PepE.

Interactions:
- van der Waals
- Conventional hydrogen bond
- Carbon hydrogen bond

Peperomin E reactivates TSGs in lung cancer

with 25 and 50 mg/kg PepE (i.e., 3.76% and 3.12% methylation, respectively) compared to the negative control (4.33% methylation). Treatment of A549 cells and xenograft tumors with 5-Aza-dC also significantly decreased global DNA methylation (Fig. 7).

The above results indicated that PepE can act as both chemical inhibitor and transcriptional modulator of DNMT1. Such activities might be attributable to its ability to block the active site and downregulate the positive transcriptional mediators (Sp1/NF-κB pathway) of the DNMT1 enzyme.

**Peperomin E demethylates tumor suppressor genes and reactivates their expressions in NSCLC cells.** One of the primary biological outcomes of DNA demethylation in cancer cells is transcriptional reactivation of silenced tumor suppressor genes (TSGs). The RASSF1A, APC, p16INK4 (in male patients), and RUNX3 genes were discovered more frequently methylated in lung tissue from NSCLC patients than non-cancerous tissue. RASSF1A and APC genes were found fully hypermethylated in A549 cells; the RUNX3 gene was found silenced in NCI-H460 cells by promoter methylation, and the promoter of p16INK4 gene was found completely methylated in H1299 cells. Demethylation of these TSGs and restoration of their expression in cancer cell lines impairs tumorigenicity. Thus, factors that restore the expression of these TSGs have immense potential in inhibiting tumor growth. As PepE inhibits DNMT1 activity and expression, we speculated that PepE might be involved in demethylation and re-expression of TSGs in NSCLC cells. We therefore investigated methylation status of RASSF1A and APC genes in A549 cells, the p16INK4 gene in H1299 cells, and the RUNX3 gene in NCI-H460 cells using methylation-specific PCR before and after PepE treatment. As expected, RASSF1A and APC genes were fully methylated in untreated A549 cells, confirming that they are completely silenced in A549 cells (Fig. 8a). Following 0.5 μM PepE treatment, there was a noticeable increase in the levels of unmethylated RASSF1A or APC compared to the control; and after 1.0 or 2.0 μM treatment, this effect was even more significant (P < 0.01, Fig. 8a). Quantitative real-time PCR analysis revealed that PepE and 5-Aza-dC each reactivated silenced RASSF1A and APC mRNA expression in a concentration-dependent manner in A549 cells (i.e., ≥74-fold for RASSF1A and ≥19 fold for APC at 2 μM dose of PepE, Fig. 8b). The findings are much the same concerning p16INK4 and RUNX3 genes. As shown in Figure 8(a), these two genes were entirely methylated in NCI-H460 and H1299 cells. After treatment with PepE, the levels of unmethylated p16INK4 and RUNX3 genes were significantly increased, whereas the methylated levels of these two genes were significantly reduced (P < 0.01). The RT-qPCR results proved that the mRNA expression of p16INK4 and RUNX3 were significantly restored in a dose-dependent manner following PepE treatment (i.e., ≥30-fold for p16INK4 and ≥87-fold for RUNX3 at 4 μM dose of PepE; Fig. 8b).

In vitro protein reactivation levels were determined using Western blot analysis. As shown in Figure 9(a), PepE and 5-Aza-dC each significantly reactivated silenced RASSF1A and APC protein levels in A549 cells in a concentration-dependent manner (P < 0.01). The protein levels of p16INK4 and RUNX3 were also significantly restored in NCI-H460 cells in a dose-dependent manner (P < 0.01). Immunohistochemical analysis showed that there was a significant increase in RASSF1A- and APC-positive cells in the tumor tissues of the 50 mg/kg PepE-treated group when compared to the control group (Fig. 9b).
According to previous studies, RASSF1A, APC, RUNX3, and p16INK4 tumor suppressors can scaffold multiple pro-apoptotic pathways and regulate cell cycle progressions in lung cancer. RASSF1A directly activates pro-apoptotic and cell cycle regulation factors in lung cancer cells including MST1/2 (pro-apoptotic serine/threonine kinases), CNK1 (a pro-apoptotic adapter protein), MOAP-1 (a Bax binding protein), and cyclin D1. APC can directly destroy β-catenin (a crucial regulating protein of Wnt signaling pathway), thus promoting apoptosis and cell cycle arrest of NSCLC cells. RUNX3 can induce NSCLC cell apoptosis by blocking the transforming growth factor-β superfamily signaling pathway. p16INK4 mediates apoptosis and cell cycles in NSCLC cells by direct downregulating Rb and indirectly downregulating the anti-apoptotic protein Bcl-2.

In this study, the protein levels of some of the aforementioned pro-apoptotic and cell cycle regulation factors (i.e., RASSF1A-mediated MST1/2, CNK1, and MOAP-1, and APC-mediated β-catenin) were also investigated to further elucidate the mechanisms involved in PepE-induced apoptosis and cell cycle arrest in A549 cells. As shown in Figure S6, after PepE treatment, the protein levels of MST1, MST2, CNK1, and MOAP-1 were significantly increased, whereas β-catenin was significantly decreased in a concentration-dependent manner (P < 0.01). Immunohistochemical analysis showed that there was a significant increase in MST1-, MST2-, CNK1-, and MOAP-1-positive cells (P < 0.01) but a decrease in β-catenin-positive cells (P < 0.01) in the tumor tissues of the PepE-treated (50 mg/kg) group (Fig. S7).
Discussion

Both genetic and epigenetic events are implicated in the tumorigenesis of lung cancer. Epigenetic changes, which are reversible, are attractive targets for chemotherapeutic intervention. One of the major epigenetic alterations in lung cancer is aberrant DNA methylation in the promoter region of TSGs.\(^{(42)}\) Tumor suppressor gene silencing can promote tumorigenesis by increasing cell proliferation and suppressing apoptosis and DNA repair.\(^{(37)}\) Therefore, therapeutic strategies that target global epigenetic inactivation of TSGs have been pioneered for cancer treatment.

It has been well documented that DNMT1, together with other DNA methyltransferases, regulate and maintain DNA methylation patterns in mammalian cells. Inhibition of DNMT1 has been presented as a possible pathway to demethylation of DNA at the 5-position of cytosine and reactivation of TSGs silenced by promoter methylation.\(^{(29)}\) In this study, we first showed that PepE, a naturally derived secolignan, not only
inhibits DNMT1 enzymatic activity, but also decreases its transcription levels by blocking the active site and inhibiting the positive transcription regulators (Sp1/NF-κB pathway) of this enzyme. That is, PepE may serve dual functions: acting as both chemical inhibitor and transcriptional modulator of DNMT1. Both of these activities drive promoter demethylation, resulting in re-expression of certain silenced TSGs in NSCLC cells. It was also found that, in response to PepE treatment, NSCLC cells underwent apoptosis and became arrested at the G1 phase of the cell cycle. All the aforementioned events occur together and subsequently contribute to PepE’s anticancer effects against NSCLC, as evidenced by our in vitro and in vivo studies.

Up to now, the extensively studied DNMT inhibitors were nucleoside analogs including 5-azacytidine and 5-Aza-dC, which have been approved by the US FDA for the treatment of myelodysplastic syndrome and cutaneous T-cell lymphoma. Although no DNMT inhibitors are currently approved for treatment of lung cancer, a recently completed clinical trial combining 5-azacytidine and entinostat (a histone deacetylase inhibitor) for the treatment of advanced NSCLC demonstrated promising results. However, there are a number of additional limitations for the use of these nucleoside analogs. In particular, these drugs can cause severe side-effects, including hematopoietic toxicity and neutropenia. Furthermore, these drugs are unstable, and can be degraded by hydrolytic cleavage and deamination. In contrast, PepE, derived from nature, may be devoid of several of these limitations. According to our research data, although the demethylating activity is lower than that of the currently used agent 5-Aza-dC, PepE appears to be considerably safer in animals. Therefore, this agent might further serve as a complementary therapy, especially when used in conjunction with nucleoside analogs or in the setting of nucleoside resistance, during treatment of cancer.

In summary, we identified a new DNMT1 inhibitor, PepE, that induced DNA demethylation and reversed the silencing of certain TSGs in NSCLC cells and induced NSCLC cell apoptosis and cell cycle arrest. These findings are of importance for understanding the mechanisms of PepE against lung cancer and provides a promising epigenetically targeting agent for cancer treatment. Further mechanism of action and structural modification studies to increase the efficacy of this natural product are ongoing.

Acknowledgments
This work was supported by grants from the Natural Science Foundation of China (Grant No. 81402812) and the Natural Science Foundation of Jiangsu Province (Grant No. BK20130954).

Disclosure Statement
The authors have no conflict of interest.
References


Supporting Information

Additional Supporting Information may be found online in the supporting information tab for this article:

Fig. S1. Proton nuclear magnetic resonance (a) and carbon-13 nuclear magnetic resonance (b) spectrum of peperomin E.

Fig. S2. High-performance liquid chromatography peak purity analysis of peperomin E.

Fig. S3. In silico target fishing protocol using the LibDock module in Discovery Studio 4.0.

Fig. S4. Histopathological analysis of liver, kidney, and lung tissue structures in xenograft mice.

Fig. S5. Chromatogram using ultra-fast liquid chromatography tandem mass spectrometry of 5-methyl-deoxy-cytidine (5mdC) and deoxyguanosine (dG) in DNA of hydrolyzed A549 cells.

Fig. S6. Effects of peperomin E on changes of Ras association domain family member 1 (RASSF1A)-modulated pro-apoptotic and cell cycle arrest proteins.

Fig. S7. Effects of peperomin E on changes of adenomatous polyposis coli (APC)-modulated pro-apoptotic protein β-catenin.

Table S1. Primer list for methylation-specific PCR.

Table S2. Polymerase chain reaction amplification protocol in methylation-specific PCR test.

Table S3. Primer list for quantitative RT-PCR.

Table S4. Polymerase chain reaction amplification protocol in quantitative RT-PCR test.